1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
Google Scholar | Crossref | Medline2. Bertoli, G, Cava, C, Castiglioni, I. MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer. Int J Mol Sci 2016; 17: 421.
Google Scholar | Crossref | Medline3. Costa, PM, Pedroso, de, Lima, MC. MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression. Pharmaceuticals (Basel) 2013; 6: 1195-1220.
Google Scholar | Crossref | Medline4. Sun, Q, Zhao, X, Liu, X, et al. miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate 2014; 74: 1613–1621.
Google Scholar | Crossref | Medline5. Lin, SL, Chiang, A, Chang, D, et al. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008; 14: 417–424.
Google Scholar | Crossref | Medline | ISI6. Qin, C, Huang, RY, Wang, ZX. Potential role of miR-100 in cancer diagnosis, prognosis, and therapy. Tumour Biol 2015; 36: 1403–1409.
Google Scholar | Crossref | Medline7. Al Olama, AA, Kote-Jarai, Z, Berndt, SI, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46: 1103–1109.
Google Scholar | Crossref | Medline8. Pomerantz, MM, Shrestha, Y, Flavin, RJ, et al. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 2010; 6: e1001204.
Google Scholar | Crossref | Medline9. Wang, X, Hayes, JE, Xu, X, et al. Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing. Gene 2020: 145265.
Google Scholar10. Hu, Y, Yu, CY, Wang, JL, et al. MicroRNA sequence polymorphisms and the risk of different types of cancer. Sci Rep 2014; 4: 3648.
Google Scholar | Crossref | Medline11. Bastami, M, Choupani, J, Saadatian, Z, et al. Evidences from a systematic review and meta-analysis unveil the role of MiRNA polymorphisms in the predisposition to female neoplasms. Int J Mol Sci 2019; 20.
Google Scholar12. Damodaran, M, Paul, SFD, Venkatesan, V. Genetic polymorphisms in miR-146a, miR-196a2 and miR-125a genes and its association in prostate cancer. Pathol Oncol Res 2020; 26: 193–200.
Google Scholar | Crossref | Medline13. Chen, G, Umelo, IA, Lv, S, et al. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 2013; 8: e60317.
Google Scholar | Crossref | Medline14. Emming, S, Chirichella, M, Monticelli, S. MicroRNAs as modulators of T cell functions in cancer. Cancer Lett 2018; 430: 172–178.
Google Scholar | Crossref | Medline15. Boldin, MP, Taganov, KD, Rao, DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208: 1189–1201.
Google Scholar | Crossref | Medline | ISI16. Zhao, JL, Rao, DS, Boldin, MP, et al. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A 2011; 108: 9184–9189.
Google Scholar | Crossref | Medline | ISI17. Xu, B, Feng, NH, Li, PC, et al. A functional polymorphism in pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate 2010; 70: 467–472.
Google Scholar | Crossref | Medline18. Cazzoli, R, Buttitta, F, Di Nicola, M, et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 2013; 8: 1156–1162.
Google Scholar | Crossref | Medline19. Leite, KR, Tomiyama, A, Reis, ST, et al. MicroRNA expression profiles in the progression of prostate cancer–from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 2013; 31: 796–801.
Google Scholar | Crossref | Medline20. Zhu, Z, Wang, CP, Zhang, YF, et al. MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Asian Pac J Cancer Prev 2014; 15: 917–923.
Google Scholar | Crossref | Medline21. Feng, B, Wang, R, Chen, LB. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012; 317: 184–191.
Google Scholar | Crossref | Medline22. Salido-Guadarrama, AI, Morales-Montor, JG, Rangel-Escareño, C, et al. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Mol Med Rep 2016; 13: 4549–4560.
Google Scholar | Crossref | Medline23. Nabavi, N, Nur Saidy, NR, Venalainen, E, et al. MiR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Sci Rep 2017; 7: 1–10.
Google Scholar | Crossref | Medline24. Samli, H, Samli, M, Vatansever, B, et al. Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines. World J Urol 2019; 37: 1117–1126.
Google Scholar | Crossref | Medline25. Leite, KR, Tomiyama, A, Reis, ST, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 2011; 185: 1118–1122.
Google Scholar | Crossref | Medline | ISI26. Chen, M, Zhou, ZY, Chen, JG, et al. Effect of miR-146a polymorphism on biochemical recurrence risk after radical prostatectomy in southern Chinese population. Genet Mol Res 2014; 13: 10615–10621.
Google Scholar | Crossref | Medline27. Zhu, J, Yang, L, You, W, et al. Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China. Int J Clin Exp Pathol 2015; 8: 7332–7340.
Google Scholar | Medline28. Danesh, H, Hashemi, M, Bizhani, F, et al. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene 2018; 647: 73–78.
Google Scholar | Crossref | Medline